Dapirolizumab pegol (BIIB133), a PEGylated F(ab’) fragment that targets CD40L, was assessed in a phase 2b study (NCT02804763) involving 182 SLE patients, where they received standard of care (SOC), along with either intravenous dapirolizumab administered every 4 wk at three doses (6, 24, and 45 mg/kg), or placebo. The gene discussed is CD40LG; the disease is systemic lupus erythematosus.